Nanoscale Drugs Carriers in Chronic Diseases Treatment: Applications
DOI:
https://doi.org/10.61841/09c46w52Keywords:
Cancer Therapy, Cardiovascular Diseases, Diabetes, Nanomedicine, Stimuli Responsive, Targeted Drug DeliveryAbstract
Nanomedicines address traditional therapy shortcomings, as shown by many preclinical and clinical studies that indicate site-specific drug delivery, decreased side effects, and better treatment result. Developing appropriate and the biocompatible drug delivery vehicles is a prerequisite effectively achieved through the use of simple and functional liposomes, hydrogels, nanoparticles, and dendrimers, micelles, and mesoporous particulates. Nanomedicine plays a key role for applications like the delivery and diagnosis of drugs in the medical field. Over the last decade, the need to build multiple systems that may distribute the pharmaceutical agent accurately and directly to the target site has expanded. Across medical fields such as cardiology, oncology, and immunology these programs have a major impact. However, it still needs a large number of extensive clinical trials to make sure the short-and long-term effects of the nanomedicines in humans. Smart drug delivery systems with the stimuli response, such as temperature, pH, illumination, electrical, ultrasound, and magnetic fields were developed in this regard. Several nanoparticles, including silver NPs, gold NPs, magnetic NPs, quantum dots, and mesoporous silica NPs, have been studied as nanocarriers for drug targeting.
Downloads
References
[1] A. I Aiacoboae et al., “Applications of nanoscale drugs carriers in the treatment of chronic diseases,” in I Nanostructures for Novel Therapy: Synthesis, Characterization and Applications, 2017.
[2] J. K. Patra et al. I, “Nano based drug delivery systems: recent developments and future prospects,” I J. Nanobiotechnology, 2018.
[3] J. K. I Patra et al., “Nano based drug delivery systems: Recent developments and future prospects 1 I 0 Technology 1007 Nanotechnology 03 Chemical Sciences 0306 Physical I Chemistry (incl. Structural) 03 Chemical Sciences 0303 Macromolecular and Materials Chemistry 11 I Medical and Health Sciences 1115 Pharmacology and Pharmaceutical Sciences 09 Engineering 0903 Biomedical Engineering Prof Ueli Aebi,
Prof Peter I Gehr,” Journal of Nanobiotechnology. 2018.
[4] C. Ruggiero, L I. Pastorino, and O. L. Herrera, “Nanotechnology based targeted drug delivery,” in 2010 Annual International Conference of the IEEE Engineering in Medicine and Biology Society, I EMBC’10, 2010.
[5] B. Mukherjee, “Editorial: I nanosize drug delivery system,’” Curr I Pharm. Biotechnol., 2014.
[6] B. Mukherjee, “Nanosize I drug delivery system,” Curr. Pharm. Biotechnol., 2013.
[7] D. A. Srinivasarao, G. Lohiya, and D. S. I Katti, “Fundamentals, challenges, and nanomedicine-based I solutions for ocular diseases,” Wiley Interdisciplinary Reviews: Nanomedicine and Nanobiotechnology. 2019.
[8] L. Brannon-Peppas and J. O. Blanchette, I “Nanoparticle and targeted systems for cancer therapy,” I Advanced Drug Delivery Reviews. 2012.
[9] X. Xu, W. Ho, X. Zhang, I N. Bertrand, and O. Farokhzad, “Cancer nanomedicine: I From targeted delivery to combination therapy,” Trends in Molecular Medicine. 2015.
[10] E. Unger, T. Porter, J. Lindner, I and P. Grayburn, “Cardiovascular drug delivery I with ultrasound and microbubbles,” Advanced Drug Delivery Reviews. 2014.
[11] Drug Delivery Nanoparticles I Formulation and Characterization. 2016.
[12] A. L. Riza et al., “Clinical management of concurrent diabetes and tuberculosis I and the implications for patient services,” The Lancet I Diabetes and Endocrinology. 2014.
Downloads
Published
Issue
Section
License
This work is licensed under a Creative Commons Attribution 4.0 International License.
You are free to:
- Share — copy and redistribute the material in any medium or format for any purpose, even commercially.
- Adapt — remix, transform, and build upon the material for any purpose, even commercially.
- The licensor cannot revoke these freedoms as long as you follow the license terms.
Under the following terms:
- Attribution — You must give appropriate credit , provide a link to the license, and indicate if changes were made . You may do so in any reasonable manner, but not in any way that suggests the licensor endorses you or your use.
- No additional restrictions — You may not apply legal terms or technological measures that legally restrict others from doing anything the license permits.
Notices:
You do not have to comply with the license for elements of the material in the public domain or where your use is permitted by an applicable exception or limitation .
No warranties are given. The license may not give you all of the permissions necessary for your intended use. For example, other rights such as publicity, privacy, or moral rights may limit how you use the material.
